✦ LIBER ✦

Poster 10: A Randomized, Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington's Disease

✍ Scribed by L.J. Beglinger; W.H. Adams; H. Paulson; J.G. Fiedorowicz; D.R. Langbehn; K. Duff; A. Leserman; J.S. Paulsen

Book ID: 116800807
Publisher: Springer-Verlag
Year: 2009
Tongue: English
Weight: 41 KB
Volume: 6
Category: Article
ISSN: 1933-7213
DOI: 10.1016/j.nurt.2008.10.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Assessment of Inattention and Executive

Assessment of Inattention and Executive Dysfunction in Early Huntington’s Disease: The Atomoxetine Pilot Trial

✍ L.J. Beglinger; W.H. Adams; H. Paulson; K. Duff; J.G. Fiedorowicz; J.M. Hanson; 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 38 KB

A controlled clinical trial of baclofen

A controlled clinical trial of baclofen as protective therapy in early huntington's disease

✍ Dr. Ira Shoulson; Charles Odoroff; David Oakes; Jill Behr; David Goldblatt; Eric 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 872 KB

Poster 7: Memory for Temporal Sequences

Poster 7: Memory for Temporal Sequences for the Early Detection of Cognitive Changes in Preclinical Huntington's Disease

✍ E. Pirogovsky; B. Bartlett; A. Callazo; J. Goldstein; G. Peavy; M. Jacobson; J. 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 41 KB

A controlled randomized trial for the ev

A controlled randomized trial for the evaluation of radiotherapy in stage IV Hodgkin's disease

✍ S. Rafla; M. Coleman 📂 Article 📅 1977 🏛 Elsevier Science 🌐 English ⚖ 82 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease

✍ Kitty K. Wong; Jane E. Alty; Amanda G. Goy; Sanjay Raghav; David C. Reutens; Pet 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 565 KB

## Abstract ## Background: This randomized double blind, placebo‐controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease. ## Methods: Sixteen participants with levodopa‐induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments s

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients

✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to